Glenmark Pharmaceuticals announced that its Swiss subsidiary, Glenmark Specialty, received marketing approval from the Ministry of Health of the Russian Federation for its innovative Ryaltris Nasal Spray – a fixed-dose combination nasal spray.
This paves the way for commercialisation of Ryaltris in Russia which is expected to be made available to patients in the country in Q1 FY 2021-22.
Ryaltris (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg), is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. Ryaltris relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
In Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 18 – 38 per cent. Allergic rhinitis can impact a person’s quality of life and lead to functional impairments, as well as increase the risk of having asthma.
“Russia is one of the key markets for us and we are consistently looking to expand our product portfolio. We are delighted to receive approval for Ryaltris nasal spray in the Russian market. This new innovative addition to our portfolio is yet another major step in strengthening Glenmark’s respiratory focus in Russia and the CIS region,” said Csaba Kantor, Senior VP – Russia & CIS region, Glenmark Pharmaceuticals.